Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2007 Nov;68(6):379–399. doi: 10.1016/j.curtheres.2007.12.001

Abatacept for the treatment of rheumatoid arthritis: A review

Jeffrey L Kaine 1,1
PMCID: PMC3969965  PMID: 24692770

Abstract

Abstract

Background: Rheumatoid arthritis (RA) is a chronic, inflammatory disease affecting synovial joints. Patients with persistent, active disease have traditionally been treated with disease-modifying antirheumatic drugs (DMARDs) (eg, methotrexate) or biologic agents (eg, tumor necrosis factor [TNF] antagonists). However, patients may discontinue these treatments due to toxicity, infection, or lack of efficacy. Two additional biologic therapies—rituximab and abatacept—are currently available for TNF-antagonist inadequate responders. Abatacept is also indicated for inadequate responders to traditional DMARDs.

Objectives: The aims of this review was to provide an overview of the issues surrounding the treatment of RA patients experiencing inadequate responses to current treatment and to discuss the current and future impact of abatacept on the RA treatment armamentarium.

Methods: The MEDLINE, EMBASE, and BIOSIS databases were searched (search dates: January 1, 2000–September 19, 2007) using the terms abatacept or CTLA-4 or Orencia with rheumatoid arthritis. Full text articles in English were selected for relevance, and only articles presenting primary clinical trial data from randomized, placebo-controlled, clinical trials of abatacept were included. This review focused on the Phase III trials of abatacept in methotrexate and/or TNF-antagonist inadequate responders, as these trials had the largest number of patients and the longest study durations.

Results:The literature search initially yielded 848 papers. A total of 12 articles fulfilled the inclusion criteria. Abatacept is a novel agent that has been reported to reduce the signs and symptoms of RA in patients with active RA with an inadequate response to DMARDs and/or TNF-antagonist treatment. In both of these patient populations, treatment with abatacept was found to provide clinically meaningful health-related quality-of-life benefits, such as improvements in physical function, activity limitation, sleep, and fatigue. Abatacept was reported to have a consistent safety and tolerability profile, with a low rate (3.5%–4.2%) of discontinuation due to adverse events.

Conclusion: The efficacy and tolerability data from Phase III clinical trials suggest that abatacept is an effective and generally well tolerated treatment option for RA patients with an inadequate response to methotrexate and/or TNF antagonists.

Key words: abatacept, selective costimulation modulator, rheumatoid arthritis, inadequate responders, methotrexate, tumor-necrosis factor antagonists

Full Text

The Full Text of this article is available as a PDF (1.3 MB).

References

  • 1.Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903–911. doi: 10.1016/S0140-6736(01)06075-5. [DOI] [PubMed] [Google Scholar]
  • 2.Fuchs HA, Kaye JJ, Callahan LF. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989;16:585–591. [PubMed] [Google Scholar]
  • 3.American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 2002;46:328–346. doi: 10.1002/art.10148. [DOI] [PubMed] [Google Scholar]
  • 4.Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol. 2002;29:1631–1638. [PubMed] [Google Scholar]
  • 5.AlarcÓn GS, Tracy IC, Strand GM. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis. 1995;54:708–712. doi: 10.1136/ard.54.9.708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Mariette X, Cazals-Hatem D, Warszawki J, or the Investigators of the Club Rhumatismes et Inflammation Lymphomas in rheumatoid arthritis patients treated with methotrexate: A 3-year prospective study in France. Blood. 2002;99:3909–3915. doi: 10.1182/blood.v99.11.3909. [DOI] [PubMed] [Google Scholar]
  • 7.Menke DM, Griesser H, Moder KG. Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate. Am J Clin Pathol. 2000;113:212–218. doi: 10.1309/VF28-E64G-1DND-LF94. [DOI] [PubMed] [Google Scholar]
  • 8.Merrill JT, Shen C, Schreibman D. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: A mechanism for methotrexate- induced nodulosis in rheumatoid arthritis. Arthritis Rheum. 1997;40:1308–1315. doi: 10.1002/1529-0131(199707)40:7<1308::AID-ART16>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  • 9.Rau R, Karger T, Herborn G, Frenzel H. Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate. J Rheumatol. 1989;16:489–493. [PubMed] [Google Scholar]
  • 10.Pavelka K, Forejtová S, Pavelková A. Analysis of the reasons for DMARD therapy discontinuation in patients with rheumatoid arthritis in the Czech and Slovak republics. Clin Rheumatol. 2002;21:220–226. doi: 10.1007/s10067-002-8289-0. [DOI] [PubMed] [Google Scholar]
  • 11.Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol. 1990;17:994–1002. [PubMed] [Google Scholar]
  • 12.Humira (adalimumab)prescribing information.http://www.rxabbott.com/pdf/ humira.pdf. Accessed November 30, 2007.
  • 13.Remicade (infliximab) prescribing information. http://www.remicade.com/remicade/ assets/Med_Guide.pdf. Accessed November 30, 2007.
  • 14.Enbrel (etanercept) prescribing information. http://www.enbrel.com/prescribing- information.jsp. Accessed November 30, 2007.
  • 15.Kineret (anakinra) prescribing information. http://www.kineretrx.com/professional/ pi.jsp. Accessed November 30, 2007.
  • 16.Lipsky PE, van der Heijde DM, St Clair EW, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
  • 17.Weinblatt ME, Keystone EC, Furst DE. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial [published correction appears in Arthritis Rheum. 2003;48:855] Arthritis Rheum. 2003;48:33–45. doi: 10.1002/art.10697. [DOI] [PubMed] [Google Scholar]
  • 18.Weinblatt ME, Kremer JM, Bankhurst AD. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]
  • 19.Durez P, Van den Bosch F, Corluy L. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: A Belgian prospective study. Rheumatology (Oxford) 2005;44:465–468. doi: 10.1093/rheumatology/keh494. [DOI] [PubMed] [Google Scholar]
  • 20.Hider SL, Bruce IN, Silman AJ, Symmons DP. Defining response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. J Rheumatol. 2005;32:6–10. [PubMed] [Google Scholar]
  • 21.Furst DE, Breedveld FC, Kalden JR. Updated consensus statement on biological agents, specifically tumour necrosis factor (alpha) (TNF [alpha]) blocking agents and interleukin-1 receptor antagonist (IL-lra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis. 2005;64:iv2–iv14. doi: 10.1136/ard.2005.044941. (Suppl 4) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23:S93–S99. (Suppl 39) [PubMed] [Google Scholar]
  • 23.van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41:1845–1850. doi: 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  • 24.Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: Bibliographic study of patient assessed health outcome measures. BMJ. 2002;324:1417. doi: 10.1136/bmj.324.7351.1417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Pincus T, Summey JA, Soraci SA., Jr Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26:1346–1353. doi: 10.1002/art.1780261107. [DOI] [PubMed] [Google Scholar]
  • 26.Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483. [PubMed] [Google Scholar]
  • 27.Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics. 2004;22:27–38. doi: 10.2165/00019053-200422001-00004. (Suppl 1) [DOI] [PubMed] [Google Scholar]
  • 28.Hyrich KL, Lunt M, Watson KD, British Society for Rheumatology Biologics Register Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum. 2007;56:13–20. doi: 10.1002/art.22331. [DOI] [PubMed] [Google Scholar]
  • 29.Iannone F, Trotta F, Montecucco C, for GISEA (Gruppo Italiano per lo Studio delle Early Arthritis) Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects [published correction appears in Ann Rheum Dis .2007;66:847] Ann Rheum Dis. 2007;66:249–252. doi: 10.1136/ard.2006.058776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Di Poi E, Perin A, Morassi MP. Switching to etanercept in patients with rheu- matoid arthritis with no response to infliximab. Clin Exp Rheumatol. 2007;25:85–87. [PubMed] [Google Scholar]
  • 31.Cohen G, Courvoisier N, Cohen JD. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007;23:795–800. [PubMed] [Google Scholar]
  • 32.Wick MC, Ernestam S, Lindblad S. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): Results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol. 2005;34:333–358. doi: 10.1080/03009740510026887. [DOI] [PubMed] [Google Scholar]
  • 33.Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 2007;46:529–532. doi: 10.1093/rheumatology/kel326. [DOI] [PubMed] [Google Scholar]
  • 34.Rituxan (rituximab) prescribing information. http://www.rituxan.com/. Accessed November 30, 2007.
  • 35.Orencia (abatacept) prescribing information. http://www.orencia.com. Accessed April 15, 2007.
  • 36.Emery P. The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin Investig Drugs. 2003;12:673–681. doi: 10.1517/13543784.12.4.673. [DOI] [PubMed] [Google Scholar]
  • 37.Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol. 2002;13:559–575. doi: 10.1681/ASN.V132559. [DOI] [PubMed] [Google Scholar]
  • 38.Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A. 1999;96:185–190. doi: 10.1073/pnas.96.1.185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol. 1993;11:191–212. doi: 10.1146/annurev.iy.11.040193.001203. [DOI] [PubMed] [Google Scholar]
  • 40.Weisman MH, Durez P, Hallegua D. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol. 2006;33:2162–2166. [PubMed] [Google Scholar]
  • 41.Genovese MC, Becker JC, Schiff M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition [published correction appears in N Engl J Med. 2005;353:22] N Engl J Med. 2005;353:1114–1123. doi: 10.1056/NEJMoa050524. [DOI] [PubMed] [Google Scholar]
  • 42.Kremer JM, Westhovens R, Leon M. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907–1915. doi: 10.1056/NEJMoa035075. [DOI] [PubMed] [Google Scholar]
  • 43.Kremer JM, Dougados M, Emery P. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial [published correction appears in Arthritis Rheum . 2005;52:33] Arthritis Rheum. 2005;52:2263–2271. doi: 10.1002/art.21201. [DOI] [PubMed] [Google Scholar]
  • 44.Kremer JM, Genant HK, Moreland LW. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med. 2006;144:865–876. doi: 10.7326/0003-4819-144-12-200606200-00003. [DOI] [PubMed] [Google Scholar]
  • 45.Moreland LW, Alten R, van den Bosch F. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46:1470–1479. doi: 10.1002/art.10294. [DOI] [PubMed] [Google Scholar]
  • 46.Weinblatt M, Combe B, Covucci A. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54:2807–2816. doi: 10.1002/art.22070. [DOI] [PubMed] [Google Scholar]
  • 47.Weinblatt M, Schiff M, Goldman A. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: A randomised clinical trial. Ann Rheum Dis. 2007;66:228–234. doi: 10.1136/ard.2006.055111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med. 1983;77:35–47. doi: 10.1016/0002-9343(83)90473-4. [DOI] [PubMed] [Google Scholar]
  • 49.Genant HK, Jiang Y, Peterfy C. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum. 1998;41:1583–1590. doi: 10.1002/1529-0131(199809)41:9<1583::AID-ART8>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  • 50.Genant HK. Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: Radiologic progression and correlation of Genant/Sharp and Larsen scoring methods. Semin Arthritis Rheum. 2001;30:26–32. doi: 10.1053/sarh.2001.23697. (Suppl 2) [DOI] [PubMed] [Google Scholar]
  • 51.Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheuma- toid arthritis. Arthritis Rheum. 1981;24:1308–1315. doi: 10.1002/art.1780241012. [DOI] [PubMed] [Google Scholar]
  • 52.Russell AS, Wallenstein GV, Li T. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis. 2007;66:189–194. doi: 10.1136/ard.2006.057018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Westhovens R, Cole JC, Li T. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 2006;45:1238–1246. doi: 10.1093/rheumatology/kel066. [DOI] [PubMed] [Google Scholar]
  • 54.Wells G, Li T, Maxwell L. Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J Rheumatol. 2007;34:280–289. [PubMed] [Google Scholar]
  • 55.Rennard SI, Fogarty C, Kelsen S, for the COPD Investigators The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:926–934. doi: 10.1164/rccm.200607-995OC. [DOI] [PubMed] [Google Scholar]
  • 56.Suissa S, Ernst P, Hudson M. TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2007 doi: 10.1016/j.pupt.2007.03.003. Published online ahead of print April 11, 2007. [DOI] [PubMed] [Google Scholar]
  • 57.Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2:602–610. doi: 10.1038/ncprheum0336. [DOI] [PubMed] [Google Scholar]
  • 58.A Phase III study of BMS-188667 in patients with active rheumatoid arthritis and inadequate response to methotrexate. http://clinicaltrials.gov/ct2/show/NCT000485 68?term=abatacept&rank=35. Accessed November 30, 2007.
  • 59.Study of abatacept (BMS-188667) in subjects with active rheumatoid arthritis on background non-biologic DMARDS (disease modifying antirheumatic drugs) who have an inadequate response to anti-TNF therapy. http://clinicaltrials.gov/ct2/show/ NCT00124982?term=NCT00124982.&rank=1. Accessed November 30, 2007.
  • 60.Abatacept and infliximab in combination with methotrexate in subjects with rheu- matoid arthritis. http://clinicaltrials.gov/ct2/show/NCT00095147?term=abatacept&r ank=13. Accessed November 30, 2007.
  • 61.BMS-188667 in children and adolescents with juvenile rheumatoid arthritis. http://clinicaltrials.gov/ct2/show/NCT00095173?term=abatacept&rank=22. Accessed November 30, 2007.
  • 62.Remission in early rheumatoid arthritis. http://clinicaltrials.gov/ct2/show/NCT0012 2382?term=abatacept&rank=26. Accessed November 30, 2007.
  • 63.A Phase III study of abatacept in Japanese subjects with rheumatoid arthritis. http://clinicaltrials.gov/ct2/show/NCT00484289?term=abatacept&rank=4. Accessed November 30, 2007.
  • 64.A study of abatacept in Japanese patients with active rheumatoid arthritis while receiving methotrexate. http://clinicaltrials.gov/ct2/show/NCT00345748?term=abatacept&rank=14. Accessed November 30, 2007.
  • 65.A Phase III study of abatacept in patients with rheumatoid arthritis,with an inade- quate response to methotrexate. http://clinicaltrials.gov/ct2/show/NCT00409838?term= abatacept&rank=11. Accessed November 30, 2007.

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES